Allergic Conjunctivitis: Clinical Trials

26 trials for Allergic Conjunctivitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed. 26 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 226Completed 26
Phase 11Completed 1
Phase 31Completed 1

Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Of TL-925 For The Treatment of AC
TL-925, Placebo - Allergic Conjunctivitis
Phase 2CompletedTelios Pharma, Inc.802024-04-112024-07-03
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
VSJ-110, Placebo - Allergic Conjunctivitis
Phase 2CompletedVanda Pharmaceuticals472020-11-212025-09-11
Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Eye Drops, Solution in Single-Dose Container - Allergic Conjunctivitis, Allergic Rhinitis
Phase 2CompletedMarinomed Biotech AG642020-08-042022-08-25
Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
Intra-lymphatic allergenic extract, Intra-lymphatic placebo - Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis
Phase 2CompletedChristopher Thompson, MD212018-09-282021-04-20
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis
Phase 1 / Phase 2CompletedAldeyra Therapeutics, Inc.522018-09-082025-04-08
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
PR013 (0.045%), PR013 (0.06%), Vehicle - Allergic Conjunctivitis
Phase 2CompletedRealm Therapeutics, Inc.962017-12-102020-01-29
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
PRT-2761 0.5%, PRT-2761 1%, Patanol - Allergic Conjunctivitis
Phase 2CompletedORA, Inc.1202017-10-132022-10-17
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6% - Allergic Conjunctivitis
Phase 2CompletedFaes Farma, S.A.1212017-07-202023-03-16
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
ST266, Saline (0.9% NaCl) - Allergic Conjunctivitis
Phase 2CompletedNoveome Biotherapeutics, formerly Stemnion702016-12-012023-04-10
A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
NS2 Ophthalmic Drops (0.5%), NS2 Ophthalmic Drops Vehicle (0.0%) - Allergic Conjunctivitis, Seasonal Allergies
Phase 2CompletedAldeyra Therapeutics, Inc.1002015-08-012023-12-05
Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, Dexamethasone Ophthalmic Suspension, 0.1% - Allergic Conjunctivitis
Phase 2CompletedAlcon Research2242014-04-012015-08-24
A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
Active Comparator EBI-005 5 mg/mL, Placebo Comparator - Allergic Conjunctivitis
Phase 2CompletedEleven Biotherapeutics1502014-02-012014-07-11
AGN-229666 for the Treatment of Allergic Conjunctivitis
AGN-229666, vehicle of AGN-229666 - Allergic Conjunctivitis
Phase 2CompletedAllergan902012-10-012014-02-04
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
RX-10045, Vehicle for RX-10045 arm - Allergic Conjunctivitis
Phase 2CompletedC.T. Development America, Inc.602012-07-012013-02-08
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
SPARC1102 I, SPARC1102 II, SPARC1102 III - Allergic Conjunctivitis
Phase 2CompletedSun Pharma Advanced Research Company Limited1222011-06-012016-06-24
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
AC-170 0.05%, AC-170 0.1%, AC-170 0.24% - Allergic Conjunctivitis
Phase 2 / Phase 3CompletedAciex Therapeutics, Inc.1012011-04-012017-08-30
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025% - Allergic Conjunctivitis
Phase 2CompletedEye Therapies, LLC682011-01-012012-03-06
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution - Allergic Conjunctivitis
Phase 2CompletedBausch & Lomb Incorporated2452010-06-012020-09-14
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis
CsA high dose, CsA low dose, PA - Allergic Conjunctivitis
Phase 2CompletedFovea Pharmaceuticals SA7162010-05-012012-03-09
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CACâ„¢ Model
AC-150 Combo, AC-150A 0.1%, AC-150B 0.005% - Allergic Conjunctivitis
Phase 2CompletedAciex Therapeutics, Inc.832010-05-012017-09-14

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Conjunctivitis, Allergic (26)  ·  Rhinitis, Allergic, Seasonal (3)  ·  Conjunctivitis (2)  ·  Hypersensitivity (2)  ·  Rhinitis, Allergic (2)  ·  Lacerations (1)

Broader conditions

Conjunctival Diseases (26)  ·  Eye Diseases (26)  ·  Hypersensitivity, Immediate (26)  ·  Immune System Diseases (26)  ·  Conjunctivitis (24)  ·  Hypersensitivity (24)  ·  Nose Diseases (4)  ·  Otorhinolaryngologic Diseases (4)  ·  Respiratory Hypersensitivity (4)  ·  Respiratory Tract Diseases (4)  ·  Rhinitis (4)  ·  Rhinitis, Allergic (2)  ·  Wounds and Injuries (1)

Interventions

Dexamethasone (2)  ·  Methylprednisolone (2)  ·  BID protein, human (1)  ·  Ketotifen (1)  ·  Lubricant Eye Drops (1)  ·  Olopatadine Hydrochloride (1)  ·  Ophthalmic Solutions (1)  ·  Sodium Chloride (1)  ·  Solutions (1)  ·  Transdermal Patch (1)  ·  bilastine (1)  ·  isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (1)  ·  lifitegrast (1)  ·  prednisolone acetate (1)

Sponsors

Aciex Therapeutics, Inc. (2)  ·  Alcon Research (2)  ·  Aldeyra Therapeutics, Inc. (2)  ·  Bausch & Lomb Incorporated (2)  ·  Faes Farma, S.A. (2)  ·  Fovea Pharmaceuticals SA (2)  ·  Allergan (1)  ·  C.T. Development America, Inc. (1)  ·  Christopher Thompson, MD (1)  ·  Eleven Biotherapeutics (1)  ·  Eye Therapies, LLC (1)  ·  Marinomed Biotech AG (1)  ·  Noveome Biotherapeutics, formerly Stemnion (1)  ·  ORA, Inc. (1)  ·  Realm Therapeutics, Inc. (1)

Countries

United States (20)  ·  Canada (2)  ·  Austria (1)  ·  Japan (1)

Top investigators

Gail L Torkildsen, MD (2)  ·  Gail Torkildsen, MD (2)  ·  Alessandra Cesano, MD (1)  ·  Ander Sologuren, MD (1)  ·  Christopher Thompson, MD (1)  ·  Eva Prieschl-Grassauer, PhD (1)  ·  Jean-Philippe Combal, PharmD (1)  ·  Marie-Louise Jacques, MD MBA (1)  ·  Michael Goldstein, MD (1)  ·  Michela Palmer (1)  ·  Nicholas P Marsico, MD (1)  ·  Paul Ratner, MD (1)  ·  Peter Couroux (1)

Results publications

PMID 23484763, PMID 28007090, PMID 32407947, PMID 35585427, PMID 39386177

NIH funding

2019 (1)